other material
confidence high
sentiment positive
materiality 0.65
NewAmsterdam Pharma obtains composition of matter patent for obicetrapib extending IP to July 2043
NewAmsterdam Pharma Co N.V.
- USPTO issued patent 12,006,305 covering amorphous obicetrapib hemicalcium, the product form for potential commercialization.
- Patent protection extends to July 2043, over 9 years beyond prior second-generation patent expiration in 2034.
- Nine total patents now issued or allowed by USPTO covering obicetrapib and its uses.
- Patent eligible for listing in FDA Orange Book as drug substance patent if product approved.